Articles On Dimerix (ASX:DXB)

Dimerix (ASX:DXB) has announced that an independent Data Safety Monitoring Board (DSMB) has successfully concluded a review of the ACTION3 phase 3 clinical trial. 

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Dimerix (ASX:DXB) has confirmed the outcomes of a meeting with the US FDA to discuss the paediatric plan for its DMX-200 in Focal Segmental Glomerulosclerosis (FSGS) patients under 18 years old.

The US Food and Drug Administration (FDA) has confirmed adolescent children can be recruited to Dimerix’s ACTION3 global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial. Dimerix (ASX:DXB) today announced details of a meeting with t...

Dimerix (DXB) receives the green light to include paediatric patients in its ACTION3 study of FSGS The company confirmed the US FDA has recommended the evaluation of DMX200 in adolescent patients aged 12 to 17 years in its phase three st...

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

Dimerix (ASX:DXB) has confirmed that the recruitment of the first 72 patients in its DMX-200 ACTION3 Phase 3 trial in patients with FSGS kidney disease has been achieved.

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

New trials confirm Dimerix’s DMX-200 is safe in treating COVID-19 patients, results that are both in line with previous studies and consistent with the existing safety profile already known about the company’s flagship drug in other indicat...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. Pandemic recovery stocks like CTD and sports betting tech Blubet shone, while COVID play JB Hi-Fi continues to show growth. Here’s so...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Finding effective treatments for kidney disease  has become a hot area among pharmaceutical companies globally and Aussie clinical stage biotech Dimerix has become a leader in the race.  With growing rates of kidney disease and the burden...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment i...

Dimerix (ASX: DXB) says the CLARITY 2.0 investigator-led study of COVID-19 patients has concluded recruitment.

Dimerix (DX8) closes recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so as to allow for more efficient analyses and reporting The company is trialling its DMX-200 product as a potential new treatment for respiratory c...

Dimerix has announced a second key study for the treatment of Covid-19 has concluded recruitment. Aussie clinical stage biotech Dimerix (ASX:DXB) has announced the  CLARITY  2.0 led study of  Covid-19  patients has concluded recruitment, e...

Dimerix has announced a new patent family application to protect the results from its mouse study of DMX-700 in COPD. Aussie clinical stage biotech Dimerix (ASX:DXB) has just announced a new patent family application to protect the surprisi...

Dimerix (DXB) submits a new patent family application for its flagship DMX-700 used to treat chronic obstructive pulmonary disease The application follows after the company’s recently announced 80 per cent reduction versus control in indu...

Highlights Dimerix has taken a crucial step towards bolstering its IP position. The biopharmaceutical company has announced a new patent family application for DMX-700 for COPD. DMX-700 achieved a statistically significant 80% reducti...

Highlights Dimerix has taken a crucial step towards bolstering its IP position. The biopharmaceutical company has announced a new patent family application for DMX-700 for COPD. DMX-700 achieved a statistically significant 80% reduction v...

Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Dimerix (ASX: DXB) has announced new data showing the efficacy of its pipeline program, DMX-700, in an industry-standard preclinical model of chronic obstructive pulmonary disease.

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

Dimerix continues to develop new therapies in areas with unmet medical needs for global markets, now showing potential as a treatment for chronic obstructive pulmonary disease (COPD). Aussie clinical stage biotech Dimerix (ASX:DXB)  today a...

Dimerix (DXB) releases its pipeline program DMX-700 study results which indicates a significant 80 per cent reduction in lung injury in mice The study showed “very encouraging and statistically significant” pre-clinical data that strongly...

Recruitment into a key study into Dimerix’s DMX-200 in all COVID-19 patients has now closed with results expected to start being analysed shortly. Aussie clinical stage biotech Dimerix (ASX:DXB)  today announced that REMAP-CAP has formally...

Dimerix (DXB) formally closes recruitment of moderate state COVID-19 patients for REMAP-CAP’s renin angiotensin system (RAS) domain clinical study This is to allow for the full results of this domain to be analysed and reported, which incl...

Dimerix (ASX:DXB) has entered into an agreement with The Australian Centre for Accelerating Diabetes Innovations to progress its DMX-200 into a new clinical trial in patients with diabetic kidney disease.

Dimerix will work with a key Australian diabetic organisation to start a trial on patients with diabetic kidney disease, in which there are currently no effective treatments. Aussie clinical stage biotech Dimerix (ASX:DXB) has entered into...

Dimerix (DXB) partners with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its DMX-200 drug in a new clinical trial in patients with diabetic kidney disease The company says this trial provides a potential mark...

Dimerix (ASX:DXB) has announced the recruitment of the first patient to its DMX-200 phase 3 trial in patients with FSGS kidney disease.

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

Dimerix (DXB) recruits the first patient to its ACTION3 phase 3 DMX-200 clinical trial in patients with FSGS kidney disease The trial is randomised, double-blind and placebo-controlled to evaluate the efficacy and safety of patients with F...

The ACTION3 Phase 3 clinical trial conducted by Dimerix will study the effects of its lead drug, DMX-200, on patients with FSGS kidney disease. Aussie clinical stage biotech Dimerix (ASX:DXB) has completed a significant milestone in its  AC...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

Dimerix (ASX:DXB) has received approval from the US FDA to proceed with the Phase 3 study of DMX-200 in patients with focal segmental glomerulosclerosis.

Dimerix (DXB) receives approval from the US FDA to proceed with a phase three study of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) An Investigational New Drug (IND) application for the study, dubbed ACTION3, is now a...

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

The company also added some important updates post quarter-end for its leading Phase 3 FSGS study. Clinical stage biotech Dimerix (ASX:DXB) confirmed another round of strong progress in its globally recognised development pathway, with the...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...